Predictive impact of RNF43 mutation (mut) in patients (pts) with pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) treated with target therapy (TT) or chemotherapy (CT)

被引：0
|
作者：
Germani, Marco Maria
Moretto, Roberto
Montana, Javier Ros
Intini, Rossana
Ghelardi, Filippo
Vetere, Guglielmo
Toledo, Rodrigo De Almeida
Bergamo, Francesca
Randon, Giovanni
Elez, Elena
Lonardi, Sara
Oldani, Simone
Giordano, Mirella
Rossini, Daniele
Bravo, Walter Ferrari
Ricagno, Gianmarco
Ugolini, Paola Vignali Clara
Fontanini, Gabriella
Cremolini, Chiara
机构：
[1] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[2] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
[3] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
[4] Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[5] IRCCS, Dept Oncol, Med Oncol 1, Veneto Inst Oncol IOV, Padua, Italy
[6] Fdn IRCCS Ist Nazl Tumori Milano, Dept Med Oncol, Milan, Italy
[7] Vall dHebron Univ Hosp, Barcelona, Spain
[8] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[9] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3569
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Clinical outcomes of patients (Pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated with first-line (1L) chemotherapy regimens
    Parikh, A.
    Tabernero, J.
    Vieira, M. C.
    Kponee-Shovein, K.
    Li, B.
    Cheng, M.
    Liu, J.
    Kang, H.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S44 - S45
  • [22] Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
    Atreya, Chloe Evelyn
    Van Cutsem, Eric
    Bendell, Johanna C.
    Andre, Thierry
    Schellens, Jan H. M.
    Gordon, Michael S.
    McRee, Autumn Jackson
    O'Dwyer, Peter J.
    Muro, Kei
    Tabernero, Josep
    van Geel, Robin
    Sidhu, Roger
    Greger, James G.
    Rangwala, Fatima A.
    Motwani, Monica
    Wu, Yuehui
    Orford, Keith W.
    Corcoran, Ryan Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study
    Kopetz, S.
    Murphy, D. A.
    Pu, J.
    Yaeger, R.
    Ciardiello, F.
    Desai, J.
    Van Cutsem, E.
    Wasan, H. S.
    Yoshino, T.
    Alkuzweny, B.
    Xie, T.
    Zhang, X.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S681 - S682
  • [24] A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in Combination Trial) study.
    Desai, Jayesh
    Markman, Ben
    Ananda, Sumitra
    Tebbutt, Niall C.
    Michael, Michael
    Solomon, Benjamin J.
    McArthur, Grant A.
    Tie, Jeanne
    Gibbs, Peter
    Ritchie, David
    Koldej, Rachel
    Herschtal, Alan
    Columbus, Ruth
    Ashley, David M.
    Lundy, Joanne
    Kwan, Edmond Michael
    Waring, Paul Michael
    Tran, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Serum Uric Acid Level May Be a Predictive Factor for BRAF V600E Mutation in Older Patients with Metastatic Colorectal Cancer: An Exploratory Analysis
    Alkan, Ali
    Doganer, Gumran Ilay
    Tanriverdi, Ozgur
    ONCOLOGY, 2024, 102 (11) : 952 - 959
  • [26] INFLUENCE OF BRAF V600E AND DIFFERENT KRAS MUTATIONS ON OUTCOME OF METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FIRST- LINE THERAPY
    Rebersek, Martina
    Boc, Marko
    Hlebanja, Zvezdana
    Volk, Neva
    Benedik, Jernej
    Ebert, Maja
    Mesti, Tanja
    Ocvirk, Janja
    ANNALS OF ONCOLOGY, 2012, 23 : 24 - 24
  • [27] Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study
    Desai, Jayesh
    Kopetz, Scott
    Murphy, Danielle A.
    Pu, Jie
    Ciardiello, Fortunato
    Grothey, Axel
    Van Cutsem, Eric
    Wasan, Harpreet Singh
    Yaeger, Rona
    Yoshino, Takayuki
    Chantrill, Lorraine
    Tebbutt, Niall
    Strickland, Andrew
    Price, Timothy
    Karapetis, Chris
    Murphy, Felicity
    Donahue, Amber C.
    Golden, Adele
    Gollerkeri, Ashwin
    Zhu, Zhou
    Tabernero, Josep
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 89 - 89
  • [28] Differential radiographic appearance of BRAF V600E mutant metastatic colorectal cancer (mCRC) in patients matched by primary tumor location.
    Greene, Claire
    Atreya, Chloe Evelyn
    McWhirter, Ryan
    Ikram, Nabia
    Van Loon, Katherine
    Venook, Alan P.
    Yeh, Benjamin M.
    Behr, Spencer
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [29] BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILDTYPE METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Cremolini, C.
    Loupakis, F.
    Perrone, G.
    Ruzzo, A.
    Rulli, E.
    Garavaglia, D.
    Bencardino, K.
    Fornaro, L.
    Vincenzi, B.
    Stasi, I
    Masi, G.
    Santini, D.
    Vasile, E.
    Salvatore, L.
    Baldi, G. G.
    Spoto, C.
    Tonini, G.
    Floriani, I
    Graziano, F.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20
  • [30] Treatment pathways in patients with BRAF V600E mutated metastatic colorectal cancer: German and Austrian subgroups of the retrospective CAPSTAN CRC study
    Virchow, I.
    Hegewisch-Becker, S.
    Nusch, A.
    Jacobasch, L.
    Prager, G.
    Tschmelitsch, J.
    Welslau, M.
    Wolff, T.
    Reichenbach, F.
    Arnold, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 315 - 315
12345